Division of Rheumatology, Immunology, and Allergy; Department of Medicine, Brigham and Women's Hospital, Boston, Mass; Harvard Medical School, Boston, Mass.
Harvard Medical School, Boston, Mass; Division of Immunology, Department of Medicine, Boston Children's Hospital, Boston, Mass.
J Allergy Clin Immunol Pract. 2014 Jan-Feb;2(1):13-9; quiz 20. doi: 10.1016/j.jaip.2013.11.007.
Advances in the understanding of various malignancies and chronic inflammatory diseases has led to the development of better treatment options for prolonging patient survival and minimizing morbidity. The recognition of "first-line" chemotherapy and monoclonal agents for these conditions has given more urgency to the need to re-administer these drugs in cases of drug hypersensitivity reactions. Therefore, in these cases, not only is desensitization considered when there is no alternative therapy available but also when alternative treatments are considered therapeutically inferior and/or more toxic. In this article, we describe the steps involved in the evaluation of these patients, factors to consider before making a decision to desensitize, the implementation of desensitization protocols, and the outcomes of such procedures.
对各种恶性肿瘤和慢性炎症性疾病的认识的提高，导致了更好的治疗选择的发展，以延长患者的生存时间并最大限度地减少发病率。对这些疾病的“一线”化疗和单克隆药物的认识，使得在药物过敏反应的情况下重新使用这些药物的需求更加紧迫。因此，在这些情况下，不仅在没有替代疗法可用时考虑脱敏，而且在替代治疗被认为治疗效果较差和/或毒性更大时也考虑脱敏。在本文中，我们描述了评估这些患者的步骤，在决定脱敏之前需要考虑的因素，脱敏方案的实施，以及这些程序的结果。
